# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K243374   
B Applicant Instrumentation Laboratory (IL) Co.   
C Proprietary and Established Names HemosIL CL HIT-IgG(PF4-H)   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LCO</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 864.7695 -Platelet Factor 4Radioimmunoassay</td><td rowspan=1 colspan=1>HE - Hematology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Clearance of a new device   
B Measurand: Anti-PF4/Heparin IgG Antibodies   
C Type of Test: Qualitative assay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

HemosIL CL HIT-lgG(PF4-H) is a qualitative, fully automated, chemiluminescent immunoassay (CIA) for the detection of IgG antibodies that react with Platelet Factor 4 (PF4) when complexed to heparin. The assay is for use in human $3 . 2 \%$ citrated plasma on the ACL TOP 970 CL in a laboratory setting.

The result provided by the assay should be interpreted as either positive or negative based on the assay cut-off $\mathrm { { 1 . 0 0 U / m L } ) }$ ). The positive or negative result aids in determining the risk for heparin-induced thrombocytopenia (HIT) when used in conjunction with other laboratory and clinical findings.

Anti-PF4/Heparin antibodies are commonly found in patients with HIT. For use in adult population suspected of HIT. Not for use in isolation to exclude HIT.

For prescription use only.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements: ACL TOP 970 CL (K221359)

# IV Device/System Characteristics:

# A Device Description:

The HemosIL CL HIT-IgG(PF4-H) kit consists of:

• CL HIT-IgG(PF4-H) Cartridge: 1 cartridge containing 1 vial of magnetic particle suspension coated with PF4/PVS complex, 1 vial of assay buffer, 1 vial of tracer consisting of an mAb anti-human IgG antibody labeled with isoluminol, and 1 vial of sample diluent used for the regular predilution of the sample. The reagents are in a phosphate or HEPES buffer containing bovine serum albumin, bovine fetal serum, PF4/PVS complex, mouse monoclonal IgG, stabilizers, and preservative.

CL HIT-IgG(PF4-H) Calibrator $1 \colon 1 \mathrm { ~ x ~ } 1 . 2 \mathrm { ~ m L ~ }$ barcoded vial of a solution with humanized mAb anti-PF4-Heparin in Tris buffer containing bovine serum albumin, stabilizers and preservative.

CL HIT-IgG(PF4-H) Calibrator $2 \colon 1 \mathrm { ~ x ~ } 1 . 2 \mathrm { ~ m L ~ }$ barcoded vial of a solution with humanized mAb anti-PF4-Heparin in Tris buffer containing bovine serum albumin, stabilizers, and preservative.

The calibrators are lot specific, and they cannot be used with other lots of reagents.

# B Principle of Operation:

HemosIL CL HIT-lgG(PF4-H) assay is a chemiluminescent two-step immunoassay consisting of magnetic particles coated with PF4 complexed to polyvinyl sulfonate (PVS) which capture PF4/H antibodies from the sample, if present.

After incubation, magnetic separation, and a wash step, a tracer consisting of an isoluminollabeled anti-human IgG antibody is added and may bind with the captured PF4/H IgG on the particles. After a second incubation, magnetic separation, and a wash step, reagents that trigger the luminescent reaction are added, and the emitted light is measured as relative light units (RLUs) by the ACL TOP 970 CL optical system. The RLUs are directly proportional to the PF4/H IgG concentration in the sample.

The HemosIL CL HIT-lgG(PF4-H) assay utilizes a 4 Parameter Logistic Curve fit (4PLC) data reduction method to generate a Master Curve. The Master Curve is predefined and lot dependent and it is stored in the instrument through the cartridge barcode. With the measurement of calibrators, the predefined Master Curve is transformed to a new, instrument specific 4PLC Working Curve. The concentration values of the calibrators are included in the reagent kit calibrator value sheet 2D barcode.

# V Substantial Equivalence Information:

A Predicate Device Name(s): HemosIL AcuStar HIT-IgG(PF4-H), HemosIL AcuStar HIT Controls   
B Predicate 510(k) Number(s): K170854

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K243374</td><td colspan="1" rowspan="1">K170854</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">HemosIL CL HIT-IgG(PF4-H)</td><td colspan="1" rowspan="1">HemosIL AcuStar HIT-IgG(PF4-H)HemosIL AcuStar HITControls</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications ForUse</td><td colspan="1" rowspan="1">HemosIL CL HIT-IgG(PF4-H)is a qualitative, fullyautomated,chemiluminescentimmunoassay (CIA) for thedetection of IgG antibodiesthat react with PlateletFactor 4 (PF4) whencomplexed to heparin. Theassay is for use in human3.2% citrated plasma on theACL TOP 970 CL in alaboratory setting. Theresult provided by the assayshould be interpreted aseither positive or negative</td><td colspan="1" rowspan="1">HemosIL AcuStar HIT-IgG(pF4-H) is a qualitative,fully automated,chemiluminescentimmunoassay (CIA) for thedetection of IgG antibodiesthat react with PlateletFactor 4 (PF4) whencomplexed to heparin. Theassay is for use in human3.2% or 3.8% citratedplasma and serum on theACL AcuStar instrument ina laboratory setting. Theresult provided by theassay should be interpreted</td></tr><tr><td colspan="1" rowspan="1">′</td><td colspan="1" rowspan="1">based on the assay cut-off(1.00 U/mL). The positiveor negative result aids indetermining the risk forheparin inducedthrombocytopenia (HIT)when used in conjunctionwith other laboratory andclinical findings. Anti-PF4/Heparin antibodies arecommonly found in patientswith HIT. For use withadult population suspectedof HIT. Not for use inisolation to exclude HIT.For prescription use only.</td><td colspan="1" rowspan="1">as either positive ornegative based on the assaycut-off (1.00 U/mL). Thepositive or negative resultaids in determining the riskfor heparin inducedthrombocytopenia (HIT)when used in conjunctionwith other laboratory andclinical findings. Anti-PF4/Heparin antibodies arecommonly found inpatients with HIT. For usein adult populationsuspected of HIT. Not foruse in isolation to excludeHIT.For prescription use.</td></tr><tr><td colspan="1" rowspan="1">Product code</td><td colspan="1" rowspan="1">LCO</td><td colspan="1" rowspan="1">LCO</td></tr><tr><td colspan="1" rowspan="1">Measurand</td><td colspan="1" rowspan="1">Anti-PF4/Heparin IgGAntibodies</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Chemiluminescentimmunoassay (CIA)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagents</td><td colspan="1" rowspan="1">Cartridge containingmagnetic particlesuspension coated with PF4complexed to polyvinylsulfonate (PVS)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antibodies</td><td colspan="1" rowspan="1">Mouse monoclonal anti-human IgG antibody</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Isoluminol conjugated anti-human IgG</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cut-off</td><td colspan="1" rowspan="1">Positive: ≥ 1.00 U/mLNegative: &lt; 1.00 U/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Human 3.2% citratedplasma</td><td colspan="1" rowspan="1">Human citrated (3.2 and3.8%) plasma and serum</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">ACL TOP 970 CL</td><td colspan="1" rowspan="1">ACL AcuStar</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Two calibrator levels(included in the kit):Calibrator 1 target value:1.00 U/mL</td><td colspan="1" rowspan="1">Two calibrator levels(included in the kit):Calibrator 1 target value:1.00 U/mL</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Calibrator 2 target value:16.50 U/mL</td><td colspan="1" rowspan="1">Calibrator 2 target value:16.00 U/mL</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Two control levels (soldseparately, liquid format):Low Control target value:0.60 U/mLHigh Control target value:3.50 U/mL</td><td colspan="1" rowspan="1">Two control levels (soldseparately, liquid format):Low Control target value:0.60 U/mLHigh Control target value:3.00 U/mL</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline−Third Edition CLSI EP07-Ed.3: Interference Testing in Clinical Chemistry−Third Edition   
• CLSI EP12-A2: User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline−Second Edition.   
• CLSI EP25-A2: Evaluation of Stability of In Vitro Medical Laboratory Test Reagents−Second Edition CLSI EP28-A3: Defining Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline−Third Edition CLSI EP37-Ed1: Supplement Tables for Interference Testing in Clinical Chemistry−First Edition

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Repeatability:

An internal precision study was performed using two (2) controls and five (5) plasma sample pools on two ACL TOP $9 7 0 \mathrm { C L }$ instruments (The controls were run on one (1) ACL TOP $9 7 0 \mathrm { C L }$ instrument and the plasma sample pools on a second ACL TOP $9 7 0 \mathrm { C L }$ ). Each sample was tested with three (3) lots of HemosIL CL HIT-IgG(PF4-H) reagent cartridges for 20 days, with two (2) runs a day and two (2) replicates per run, yielded $\Nu { = } 8 0$ replicates per sample for each reagent cartridge lot as summarized below.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(UmL)</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=2>RepeatabilityBetween-Run</td><td rowspan=1 colspan=2>RepeatabilityBetween-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Plasma SampleA (pool)</td><td rowspan=1 colspan=1>0.272</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>8.1%</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>11.3%</td></tr><tr><td rowspan=1 colspan=1>Plasma SampleB (pool)</td><td rowspan=1 colspan=1>0.777</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>14.5%</td><td rowspan=1 colspan=1>0.122</td><td rowspan=1 colspan=1>15.6%</td></tr><tr><td rowspan=1 colspan=1>Plasma SampleC (pool)</td><td rowspan=1 colspan=1>1.210</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.020</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.118</td><td rowspan=1 colspan=1>9.7%</td><td rowspan=1 colspan=1>0.137</td><td rowspan=1 colspan=1>11.3%</td></tr><tr><td rowspan=1 colspan=1>Plasma Sample D(unadulterated)</td><td rowspan=1 colspan=1>1.817</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.082</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>0.137</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=1 colspan=1>Plasma SampleE (pool)</td><td rowspan=1 colspan=1>21.451</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.618</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.386</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.632</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>2.031</td><td rowspan=1 colspan=1>9.5%</td><td rowspan=1 colspan=1>2.248</td><td rowspan=1 colspan=1>10.5%</td></tr><tr><td rowspan=1 colspan=1>High Multi-Ab Control</td><td rowspan=1 colspan=1>3.260</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.073</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.161</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=1 colspan=1>Low Multi-AbCControl</td><td rowspan=1 colspan=1>0.440</td><td rowspan=1 colspan=1>239</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>6.1%</td></tr></table>

Qualitative Agreement Summary   

<table><tr><td rowspan=1 colspan=1>Sample Description</td><td rowspan=1 colspan=1>ExpectedStatus</td><td rowspan=1 colspan=1>TotalReplicates</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Plasma Sample A</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>0/320</td><td rowspan=1 colspan=1>320/320</td></tr><tr><td rowspan=1 colspan=1>Plasma Sample B</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>3/320</td><td rowspan=1 colspan=1>317/320</td></tr><tr><td rowspan=1 colspan=1>Plasma Sample C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>320/320</td><td rowspan=1 colspan=1>0/320</td></tr><tr><td rowspan=1 colspan=1>Plasma Sample D</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>320/320</td><td rowspan=1 colspan=1>0/320</td></tr><tr><td rowspan=1 colspan=1>Plasma Sample E</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>320/320</td><td rowspan=1 colspan=1>0/320</td></tr><tr><td rowspan=1 colspan=1>Low Multi-Ab Control</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>319*</td><td rowspan=1 colspan=1>0/319</td><td rowspan=1 colspan=1>319/319</td></tr><tr><td rowspan=1 colspan=1>High Multi-Ab Control</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>320/320</td><td rowspan=1 colspan=1>0/320</td></tr></table>

\*Failed result due to instrument error. Replicate not repeated.

# 2. Reproducibility:

Reproducibility studies were conducted at three (3) external clinical sites by four operators (minimum of 1 operator per site), on three (3) ACL TOP $9 7 0 \mathrm { C L }$ instruments (one instrument per site), using three (3) lots of HemosIL CL HIT-IgG(PF4-H) with six (6) plasma sample pools (samples 1–6) and two (2) controls (low (sample 7) and high (samples 8)). Each sample was tested in triplicate, twice a day for 5 days, for a total of 270 replicates per sample. The pooled data for each sample is presented below:

<table><tr><td rowspan=2 colspan=1>SampleID</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Between-lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>0.405</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>12.9%</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>14.4%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>0.050</td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=7>All replicates &lt; 1.00 U/mL</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>0.845</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.020</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>1.336</td><td rowspan=1 colspan=1>0.081</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.025</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.101</td><td rowspan=1 colspan=1>7.5%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>2.622</td><td rowspan=1 colspan=1>0.102</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.162</td><td rowspan=1 colspan=1>6.2%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>19.082</td><td rowspan=1 colspan=1>0.665</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.422</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.315</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.853</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>2.882</td><td rowspan=1 colspan=1>15.1%</td><td rowspan=1 colspan=1>3.123</td><td rowspan=1 colspan=1>16.4%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>0.515</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.020</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>3.487</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.121</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.080</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.193</td><td rowspan=1 colspan=1>5.5%</td></tr></table>

Qualitative Agreement Summary   

<table><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>Expected Status ofSample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>0/270</td><td rowspan=1 colspan=1>270/270</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>0/270</td><td rowspan=1 colspan=1>270/270</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>2/270</td><td rowspan=1 colspan=1>268/270</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>270/270</td><td rowspan=1 colspan=1>0/270</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>270/270</td><td rowspan=1 colspan=1>0/270</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>270/270</td><td rowspan=1 colspan=1>0/270</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>0/270</td><td rowspan=1 colspan=1>270/270</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>270/270</td><td rowspan=1 colspan=1>0/270</td></tr></table>

3. Linearity:

HemosIL CL HIT- $\mathrm { \cdot I g G _ { ( P F 4 - H ) } }$ assay is a qualitative assay and linearity is not applicable.

# 4. Analytical Specificity/Interference:

Interference study was conducted using a paired-bias approach testing each potential interfering substance on either two or three lots of HemosIL CL HIT-IgG(PF4-H) on a minimum of one ACL TOP $9 7 0 \mathrm { C L }$ at three sample levels for each substance: baseline (no interfering substance), at the intended claim, and at $20 \%$ above the intended claim (or C0, Cmax, and $C _ { \mathrm { m a x } + 2 0 \% }$ , respectively). Interfering substances were tested in three citrated plasma pools (Negative, MDL, and High Positive) with a minimum of 14 replicates per sample.

A dose-response interference study was performed for unfractionated heparin (UFH), low molecular weight heparin (LMWH), rheumatoid factor (RF), fondaparinux, and protamine. Five levels of each interferent were tested in three citrated plasma pools (Negative, MDL, and High Positive), with five (5) replicates per each level.

A cross-reactivity study was conducted with 24 patients diagnosed with Antiphospholipid Syndrome (APS) and 20 patient samples negative for APS. Samples were tested with one lot of HemosIL CL HIT-IgG(PF4-H) on the ACL TOP 970 CL.

The results of the above studies demonstrate that the HemosIL CL HIT-IgG(PF4-H) on the ACL TOP 970 CL analyzer is not affected by the interferents up to the levels indicated in table below:

<table><tr><td rowspan=1 colspan=1>Limitations/ InterferingSubstances</td><td rowspan=1 colspan=1>Concentrations up to:</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>1500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Unfractionated heparin</td><td rowspan=1 colspan=1>1.2 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Low Molecular weight heparin</td><td rowspan=1 colspan=1>2.5 IU/mL</td></tr><tr><td rowspan=1 colspan=1>HAMA</td><td rowspan=1 colspan=1>1 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>160 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Acid Citric Dextrose</td><td rowspan=1 colspan=1>0.45 g/dL</td></tr><tr><td rowspan=1 colspan=1>Argatroban</td><td rowspan=1 colspan=1>1.2 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Fondaparinux</td><td rowspan=1 colspan=1>0.102 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Dabigatran</td><td rowspan=1 colspan=1>0.900 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rivaroxaban</td><td rowspan=1 colspan=1>0.270 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Protamine</td><td rowspan=1 colspan=1>5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Antiphospholipid Syndrome</td><td rowspan=1 colspan=1>Twenty-four citrated plasma samples from patientsdiagnosed with Antiphospholipid Syndrome (APS)were tested with the HemosIL CL HIT-IgG(pF4-H) assayand four commercially available antiphospholipidantibody assays (anti-cardiolipin IgG, anti-cardiolipinIgM, anti-β2 glycoprotein I IgG, anti-β2 glycoprotein IIgM). Three out of the twenty-four samples recoveredabove the cut-off of 1.00 U/mL (positive) for HemosILCL HIT-IgG(PF4-H). These three samples also testedpositive for anti-cardiolipin IgG but tested negative forthe other three antiphospholipid assays.</td></tr></table>

5. Assay Reportable Range:

Not applicable

6. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Traceability

There is currently no International Standard available for Anti‐PF4/Heparin (PF4/H) antibodies; therefore, each manufacturer must establish their own internal standardization and reportable units. Two different types of calibrator materials are prepared for the HemosIL CL HIT‐IgG(PF4‐H) assay standardization:

• Internal Primary Reference Materials: Used internally to prepare the kit calibrators • Kit Calibrators: Used by the ACL TOP 970 CL instrument to prepare the Working Calibration Curve

HemosIL CL HIT-IgG(PF4-H) is standardized to Internal Primary Reference Material (humanized monoclonal anti PF4-Heparin antibody diluted in Tris-buffer containing negative human serum, stabilizers, and preservative). The Primary Reference Materials are shared among HemosIL CL HIT-IgG(PF4-H) and HemosIL AcuStar HIT-IgG(PF4-H) (K170854). The values were initially set on HemosIL AcuStar HIT-IgG(PF4-H) according to the following process: A population of HIT suspected samples was studied and a Receiver Operating Characteristics (ROC) analysis vs Serotonin Release Assay (SRA) showed a clear separation of negative and positive results with an optimal sensitivity and specificity using a cut-off of $1 . 0 0 \mathrm { U / m L }$ . This same value was proposed for HemosIL CL HIT-IgG(PF4-H) which was confirmed as optimal with a validation cut-off study on HemosIL CL HIT-IgG(PF4-H) assay using a population of HIT suspected samples and assessing the overall agreement vs SRA.

# Expected values

The Kit Calibrators (component of assay test kit) are prepared and assigned versus internal Primary Reference Material (RMI). The assigned concentration is obtained for each calibrator by analyzing the Kit Calibrators being manufactured referenced to their respective internal Primary Reference Material over multiple runs and instruments.

The assigned concentration must fall within the following acceptability ranges:

Calibrator $1 \colon 1 . 0 0 \pm 0 . 2 4 \ : \mathrm { U } / \mathrm { m L }$ • Calibrator 2: $1 6 . 5 0 \pm 3 . 3 0 \mathrm { U / m L }$

# Reagent stability

Reagent real-time shelf-life stability and continuous on-board stability testing was conducted using three (3) lots of HemosIL CL HIT-IgG(PF4-H) reagent cartridges with a panel of four citrated plasma samples (two sample pools and two unadulterated samples) and two control levels (low and high) at different time points, spanning the claimed stability range. Each material was analyzed in 13 replicates and compared to the results obtained from baseline day 0. The reagent stability study results support the following claim:

On-Board Stability was established at 30 days for the HemosIL CL HIT-IgG (PF4-H) at $2 { - } 8 ^ { \circ } \mathrm { C }$ continuously on-board the ACL TOP 970 CL.   
Shelf-life was established at 12 months for the HemosIL CL HIT-IgG(PF4-H) when stored at $2 { - } 8 ~ ^ { \circ } \mathrm { C }$ .

# Calibrator stability

The calibrator on-board was conducted with three (3) lots of HemosIL CL HIT-IgG(PF4-H) calibrators (1 & 2) by performing one calibration at different time points (0, 2, 4 and 5 hours) after the placement of the assay calibrators on board the ACL TOP 970 CL. Each of the HemosIL CL Multi-Ab Controls (control low and control high) was analyzed with 11 replicates. The calibrator open-vial stability studies was conducted with three (3) lots of HemosIL CL HIT-IgG(PF4-H) calibrators (1 & 2A) first placed on board the ACL TOP 970 CL for 1 hour and then re-capped and placed at $+ 2 { - } 8 ^ { \circ } \mathrm { C }$ . Calibrations were performed at time 0, 14 days, and 15 days (at $+ 2 { - } 8 ^ { \circ } \mathrm { C }$ ) with 10 replicates each of Multi-Ab Control (Low and

High). The mean values obtained for each Multi-Ab Control at each time point were compared versus the corresponding mean values obtained with the calibration at time 0. The calibrator on-board and open-vial study results support that the calibrators are stable for 4 hours on-board the ACL TOP 970 CL in the open original vial or 14 days at $2 { - } 8 ^ { \circ } \mathrm { C }$ in the closed original vial.

# Transport stability

A shipping (transport simulation) study was conducted using a total of 30 kits of HemosIL CL HIT-IgG(PF4-H) which were packed in two boxes (15 kits per box) at two stressed transport conditions. The data collected from these two shipment conditions were compared to nonstressed kits (reference kits) which were continuously maintained at the recommended storage condition of $2 { - } 8 ^ { \circ } \mathrm { C }$ . The results support warm shipment: Two days at room temperature $( 1 5 - 3 0 ^ { \circ } \mathrm { C } )$ , three days at $3 7 ^ { \circ } \mathrm { C }$ in heater followed by $2 { - } 8 ^ { \circ } \mathrm { C }$ storage until testing. HemosIL CL HIT-IgG(PF4-H) does not tolerate freezing conditions. A temperature logging device is always included in the packaging to ensure that kits can be deemed valid on receipt.

# Sample Stability

The sample stability study was performed to support the recommended storage and handling instructions found in the device labeling. Three (3) citrated plasma samples (negative sample, MDL sample and high positive sample) were tested at $2 { - } 8 ^ { \circ } \mathrm { C }$ and $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ . The study was performed using one reagent lot, with thirteen (13) replicate measurements at each time point for each sample on one ACL TOP $9 7 0 \mathrm { C L }$ instrument. The study data demonstrate that citrated plasma samples can be stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ and $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ for 8 hours before testing with the HemosIL CL HIT-IgG(PF4-H) assay.

# 7. Detection Limit:

The Limit of the Blank (LoB) and Limit of Detection (LoD) studies were performed using three different lots of HemosIL CL HIT-IgG(PF4-H) reagents on two ACL TOP 970 CL instruments, according to CLSI EP17-A2. The LoB and LoD were established at $0 . 0 9 \mathrm { U / m L }$ and $0 . 1 4 ~ \mathrm { U / m L }$ , respectively.

# 8. Assay Cut-Off:

Refer to section D. Clinical Cut-Off.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

The method comparison study was conducted at three U.S. sites with 341 samples from intended use population with confirmed medical history of a suspicion of HIT and calculation of a 4T score. Each sample was run in singlicate using the candidate assay on the ACL TOP 970 CL instrument and the predicate assay on the ACL AcuStar instrument (K170854).

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>HemosIL AcuStar HIT-IgG(PF4-H) Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=2>HemosIL CLHIT IgG(PF4-H)Results</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>92</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>249</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=1>341</td></tr><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=2>Wilson 95% CI</td></tr><tr><td rowspan=1 colspan=3>PPA (Positive PercentAgreement)</td><td rowspan=1 colspan=1>97% (91/94)</td><td rowspan=1 colspan=1>91%</td><td rowspan=1 colspan=1>99%</td></tr><tr><td rowspan=1 colspan=3>NPA (Negative PercentAgreement)</td><td rowspan=1 colspan=1>100% (246/247)</td><td rowspan=1 colspan=1>98%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=3>Total Percent Agreement</td><td rowspan=1 colspan=1>99% (337/341)</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>100%</td></tr></table>

# 2. Matrix Comparison:

Fresh vs. Frozen Sample Study Ninety-four $3 . 2 \%$ citrated plasma samples covering the range of $0 . 2 4 { - } 1 4 0 2 0 \mathrm { U } / \mathrm { m L }$ were tested for fresh/frozen equivalence at two external US sites after storage at $\leq - 2 0 ^ { \circ } \mathrm { C }$ for at least 24 hours. The study confirmed equivalence between matrices and up to two freeze/thaw cycles of the HemosIL CL HIT-IgG(PF4-H) measurement procedure on the ACL TOP $9 7 0 \mathrm { C L }$ .

# C Clinical Studies:

1. Clinical Sensitivity: NA

2. Clinical Specificity: NA

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): NA

# D Clinical Cut-Off:

The cut-off validation was conducted by qualitatively comparing the presence of anti-PF4/H antibodies as determined by HemosIL CL HIT IgG(PF4-H) to the presence of functionally relevant antibodies as determined by PF4-enhanced platelet activation assay, Serotonin Release Assay (SRA). Testing was performed with two (2) lots of HemosIL CL HIT-IgG(PF4-H) using 91 $3 . 2 \%$ citrated plasma samples (45 SRA positive and 46 SRA negative) from patients suspected of HIT with 4T scores of 1 to 3 (low), 4 to 5 (intermediate) or 6 to 8 (high) who were sent for SRA testing at one external US site.

<table><tr><td rowspan=1 colspan=1>HemosIL CL HIT-IgG(PF4-H) vs. SRA</td><td rowspan=1 colspan=1>Estimate</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=1>100.0% (45/45)</td><td rowspan=1 colspan=1>92.1%, 100.0%</td></tr><tr><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>97.8% (45/46)</td><td rowspan=1 colspan=1>88.7%, 99.6%</td></tr><tr><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>97.9% (45/46)</td><td rowspan=1 colspan=1>86.9%, 99.7%</td></tr><tr><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>100.0% (45/45)</td><td rowspan=1 colspan=1>92.1%, 100.0%</td></tr><tr><td rowspan=1 colspan=1>Overall Agreement</td><td rowspan=1 colspan=1>98.9% (90/91)</td><td rowspan=1 colspan=1>94.0%, 99.8%</td></tr></table>

# E Expected Values/Reference Range:

Reference Interval – Healthy Donors Not Heparin Exposed: A total of 122 citrated plasma samples from ostensibly healthy donors with an age range of 20 to 71 years old were tested with two lots of HemosIL CL HIT-IgG(PF4-H) on one ACL TOP $9 7 0 \mathrm { C L }$ instrument. The data were analyzed using the non-parametric quantile interval based on the order statistics. The reference interval was calculated, and the upper limit determined to be $0 . 4 5 \mathrm { U } / \mathrm { m L }$ ( $90 \%$ CI: 0.28 to 0.68 $\mathrm { U } / \mathrm { m L }$ ).

Reference Interval – Heparin Exposed, Not- HIT Suspected Patients (HIT Negative): A total number of 132 samples from patients exposed to heparin (UFH and LMWH) but not suspected of HIT with an age range of 21 to 88 years old were tested with two lots of HemosIL CL HIT-IgG(PF4-H) on one ACL TOP 970 CL instrument. The statistical method applied to analyze the data was the non-parametric quantile interval based on the order statistics. The reference interval was calculated, and the upper limit determined to be $1 . 4 2 \mathrm { U } / \mathrm { m L }$ ( $90 \%$ CI: 0.49 to $3 . 8 8 \mathrm { U / m L }$ ).

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.